BioVie Inc
BIVI1.410USD
-0.040-2.76%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
10.63MMarket Cap
LossP/E TTM
More Details of BioVie Inc Company
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
BioVie Inc Info
Ticker SymbolBIVI
Company nameBioVie Inc
IPO dateJan 14, 2014
CEODo (Viet Cuong Viet)
Number of employees13
Security typeOrdinary Share
Fiscal year-endJan 14
Address680 W Nye Lane
CityCARSON CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code89703
Phone17758883162
Websitehttps://www.bioviepharma.com/
Ticker SymbolBIVI
IPO dateJan 14, 2014
CEODo (Viet Cuong Viet)
Company Executives of BioVie Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph M. Palumbo, M.D.
Dr. Joseph M. Palumbo, M.D.
Chief Medical Officer
Chief Medical Officer
1.19K
+9.15%
Ms. Joanne Wendy Kim, CPA
Ms. Joanne Wendy Kim, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
941.00
+11.89%
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Chairman of the Board
Independent Chairman of the Board
690.00
+0.15%
Mr. Michael Edward Sherman, J.D.
Mr. Michael Edward Sherman, J.D.
Independent Director
Independent Director
208.00
--
Dr. Amy S. Chappell, M.D.
Dr. Amy S. Chappell, M.D.
Independent Director
Independent Director
--
--
Mr. Viet Cuong Do
Mr. Viet Cuong Do
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Sigmund (Sig) Rogich
Mr. Sigmund (Sig) Rogich
Independent Director
Independent Director
--
--
Mr. Bruce Mackle
Mr. Bruce Mackle
Investor Relations
Investor Relations
--
--
Mr. Kameel D. Farag
Mr. Kameel D. Farag
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph M. Palumbo, M.D.
Dr. Joseph M. Palumbo, M.D.
Chief Medical Officer
Chief Medical Officer
1.19K
+9.15%
Ms. Joanne Wendy Kim, CPA
Ms. Joanne Wendy Kim, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
941.00
+11.89%
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Chairman of the Board
Independent Chairman of the Board
690.00
+0.15%
Mr. Michael Edward Sherman, J.D.
Mr. Michael Edward Sherman, J.D.
Independent Director
Independent Director
208.00
--
Dr. Amy S. Chappell, M.D.
Dr. Amy S. Chappell, M.D.
Independent Director
Independent Director
--
--
Mr. Viet Cuong Do
Mr. Viet Cuong Do
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Diametric Capital
4.91%
Acuitas Group Holdings LLC
3.07%
Prelude Capital Management, LLC
1.92%
Prosperity Wealth Management, Inc.
1.90%
The Vanguard Group, Inc.
1.71%
Other
86.49%
Shareholders
Shareholders
Proportion
Diametric Capital
4.91%
Acuitas Group Holdings LLC
3.07%
Prelude Capital Management, LLC
1.92%
Prosperity Wealth Management, Inc.
1.90%
The Vanguard Group, Inc.
1.71%
Other
86.49%
Shareholder Types
Shareholders
Proportion
Investment Advisor
6.17%
Investment Advisor/Hedge Fund
6.06%
Hedge Fund
4.70%
Corporation
3.07%
Bank and Trust
0.99%
Individual Investor
0.29%
Other
78.71%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
133
1.35M
5.72%
--
2025Q3
143
1.35M
5.81%
+1.11M
2025Q2
143
120.00K
17.48%
+11.07K
2025Q1
149
109.16K
15.20%
-171.35K
2024Q4
150
85.67K
12.43%
-78.50K
2024Q3
141
41.11K
9.25%
-11.99K
2024Q2
134
53.11K
14.02%
-20.09K
2024Q1
127
73.20K
57.58%
+38.09K
2023Q4
122
24.68K
7.79%
+944.00
2023Q3
114
23.74K
8.66%
-1.56K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Acuitas Group Holdings LLC
231.66K
3.07%
+33.00
+0.01%
Jul 07, 2025
The Vanguard Group, Inc.
55.24K
0.73%
+1.57K
+2.93%
Jun 30, 2025
Geode Capital Management, L.L.C.
13.94K
0.18%
+138.00
+1.00%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 27, 2025
Merger
10→1
Aug 01, 2024
Merger
10→1
Aug 01, 2024
Merger
10→1
Aug 01, 2024
Merger
10→1
Aug 01, 2024
Merger
10→1
Date
Type
Ratio
Jun 27, 2025
Merger
10→1
Aug 01, 2024
Merger
10→1
Aug 01, 2024
Merger
10→1
Aug 01, 2024
Merger
10→1
Aug 01, 2024
Merger
10→1
FAQs
Who are the top five shareholders of BioVie Inc?
The top five shareholders of BioVie Inc are:
Acuitas Group Holdings LLC holds 231.66K shares, accounting for 3.07% of the total shares.
The Vanguard Group, Inc. holds 55.24K shares, accounting for 0.73% of the total shares.
Geode Capital Management, L.L.C. holds 13.94K shares, accounting for 0.18% of the total shares.
Acuitas Group Holdings LLC holds 231.66K shares, accounting for 3.07% of the total shares.
The Vanguard Group, Inc. holds 55.24K shares, accounting for 0.73% of the total shares.
Geode Capital Management, L.L.C. holds 13.94K shares, accounting for 0.18% of the total shares.
What are the top three shareholder types of BioVie Inc?
The top three shareholder types of BioVie Inc are:
Diametric Capital
Acuitas Group Holdings LLC
Prelude Capital Management, LLC
Diametric Capital
Acuitas Group Holdings LLC
Prelude Capital Management, LLC
How many institutions hold shares of BioVie Inc (BIVI)?
As of 2025Q4, 133 institutions hold shares of BioVie Inc, with a combined market value of approximately 1.35M, accounting for 5.72% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.10%.
What is the biggest source of revenue for BioVie Inc?
In --, the -- business generated the highest revenue for BioVie Inc, amounting to -- and accounting for --% of total revenue.
